Tsikloferon: solution for injections

General characteristics. Structure:

Active ingredient: 1 ml of solution contains: active agent - a meglumina акридонацетат in terms of akridonuksusny acid - 125 mg; excipient - water for injections. Description: transparent liquid of yellow color.

Pharmacological properties:

Pharmacodynamics. Tsikloferon is the low-molecular inductor of interferon that defines a wide range of its biological activity (antiviral, immunomodulatory, antiinflammatory, etc.). The main cells producers of interferon after Tsikloferon's introduction are macrophages, T - and V-lymphocytes. Depending on type of an infection dominance of activity of this or that link of immunity takes place. Drug induces high credits of interferon in the bodies and fabrics containing lymphoid elements (a spleen, a liver, lungs) activates stem cells of marrow, stimulating formation of granulocytes. Tsikloferon activates T lymphocytes and natural killerny cells, normalizes balance between subpopulations T-helperov and T - suppressors. Increases activity of α-interferon. Tsikloferon is effective concerning viruses of a tick-borne encephalitis, flu, hepatitis, herpes, a cytomegalovirus, a human immunodeficiency virus, a virus of papilloma and other viruses. At an acute viral hepatitis Tsikloferon interferes with transition of diseases to a chronic form. At a stage of primary displays of HIV infection promotes stabilization of indicators of immunity. High performance of drug in complex therapy of acute and persistent bacterial infections (neuroinfections, clamidioses, bronchitis, pneumonia, postoperative complications, urogenital infections, a peptic ulcer) as an immunotherapy component is established. Tsikloferon shows high performance at rheumatic and general diseases of connecting fabric, suppressing autoimmune reactions and having the antiinflammatory and anesthetizing effect.

Pharmacokinetics. At introduction of the most admissible dose the maximum concentration in blood is reached in 1-2 hours, in 24 hours drug is found in trace quantities. Breaks a blood-brain barrier. The elimination half-life makes 4-5 hours. Does not kumulirut in an organism at prolonged use.

Indications to use:

At adults in complex therapy: HIV - infections (stages 2A - 2B); neuroinfections: serous meningitis and encephalitis, tick-borne бореллиоз (Lyme's disease); viral hepatitis of A, B, C, D; herpes and Cytomegaloviral infection; the secondary immunodeficiences associated with acute and persistent bacterial and fungal infections; chlamydial infections; rheumatic and general diseases of connecting fabric (pseudorheumatism, system lupus erythematosus); degenerative and dystrophic diseases of joints: the deforming osteoarthrosis, etc. At children in complex therapy: viral hepatitis of A, B, C, D; herpes infection; HIV – an infection (stages 2A-2B);

Route of administration and doses:

1. At adults: Tsikloferon apply intramusculary or intravenously once a day according to the basic scheme: every other day. Duration of a course of treatment depends on a disease. 1.1 At herpes and a Cytomegaloviral infection according to the basic scheme of 10 injections on 0,25 g. Total dose of 2,5 g. Treatment is most effective at the beginning of an exacerbation of a disease. 1.2 At neuroinfections the drug is administered according to the basic scheme. A course of treatment of 12 injections on 0,25-0,5 g in combination with causal treatment. Total dose of 3-6 g. Repeated courses as required. 1.3 At a chlamydial infection enter according to the basic scheme. A course of treatment of 10 injections on 0,25 g. Total dose of 2,5 g. A repeated course of treatment in 10-14 days. Tsikloferon's combination to antibiotics is reasonable. 1.4 At an acute viral hepatitis of A, B, C, D and the mixed forms the drug is administered according to the basic scheme of 10 injections on 0,5 g. Total dose of 5,0 g. At the long course of an infection repetition of a course in 10-14 days. At a chronic viral hepatitis of B, C, D and the mixed forms the drug is administered according to the basic scheme of 10 injections on 0,5 g, further according to the supporting scheme by 3 times a week within three months as a part of complex therapy. It is recommended in combination with interferona and chemotherapy. Repetition of a course in 10 – 14 days. 1.5 At HIV – an infection (2A-2B) according to the basic scheme of 10 injections on 0,5 g and further according to the supporting scheme once in three days within 2,5 months. Repetition of a course in 10 days. 1.6 At immunodeficiency a course of treatment of 10 intramuscular injections according to the basic scheme in a single dose of 0,25 g. Total dose of 2,5 g. A repeated course is conducted in 6 – 12 months. 1.7 At rheumatic and general diseases of connecting fabric 4 courses on 5 injections according to the basic scheme on 0,25 g with a break of 10-14 days. Repeated course according to the recommendation of the doctor. 1.8 At degenerative and dystrophic diseases of joints 2 courses on 5 injections on 0,25 g with a break in 10-14 days according to the basic scheme. A repeated course according to the recommendation of the doctor. 2. At children: In pediatric practice Tsikloferon apply intramusculary or intravenously once a day according to the basic scheme: every other day. The daily therapeutic dose makes 6-10 mg/kg of body weight. 2.1 At an acute viral hepatitis of A, B, C, D and the mixed forms the drug is administered according to the basic scheme of 15 injections. At the long course of an infection repetition of a course in 10-14 days. 2.2 At a chronic viral hepatitis of B, C, D, the drug is administered according to the basic scheme of 10 injections and further according to the supporting scheme by three times a week within three months as a part of complex therapy. It is recommended in combination with interferona and chemotherapy. 2.3 At HIV – an infection (a stage 2A-2B) a course from 10 injections according to the basic scheme and further according to the supporting scheme once in three days within three months. A repeated course in 10 days. 2.4 At a herpes infection a course from 10 injections according to the basic scheme. At preservation of replikativny activity of a virus the course of treatment is continued according to the supporting scheme with introduction of times in three days within four weeks.

Features of use:

Tsikloferon does not exert impact on ability of control of vehicles. At treatment of flu and respiratory viral infections carry out symptomatic therapy. At diseases of a thyroid gland consultation of the doctor-endocrinologist is necessary.

Side effects:

Allergic reactions.

Interaction with other medicines:

Tsikloferon is compatible and is well combined with all medicines which are traditionally applied at treatment of the specified diseases (an interferona, chemotherapeutic medicines, etc.). Strengthens action of interferon and analogs of nucleosides. Reduces side effects of chemotherapy, an interferonoterapiya.

Contraindications:

Pregnancy, the lactation period, hypersensitivity to drug components, dekompensirovanny cirrhosis, children's age up to 4 years.

Overdose:

Data on overdose of drug are absent.

Storage conditions:

List B. In protected from light, the place, unavailable to children, at a temperature of 0 - 25 Pages. Freezing of solution in the course of transportation at negative temperatures does not lead to change of properties of drug. The drug defrozen at the room temperature keeps the biological and physical and chemical properties. At discoloration of solution and formation of a deposit use of drug is inadmissible. PERIOD OF VALIDITY 3 years. After expiry date use of drug is not allowed.

Issue conditions:

According to the recipe

Packaging:

Solution for intravenous and intramuscular administration of 125 mg/ml in ampoules on 2 ml. On 5 ampoules in a unilateral blister strip packaging, 1 planimetric packaging together with the application instruction and a knife for opening of ampoules or the scarificator ampoule (in the absence of a point or the line of a break on an ampoule) in a cardboard pack.